Compare · head to head
Agenus vs Exelixis
Exelixis ranks higher overall — 360 rank 96 vs 85.
Exelixis leads on Quality (82 vs 64). The two are close on Value, Safety and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Large |
| ISIN | US00847G8042 | US30161Q1040 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | — |
| Ranks | ||
| 360 | 85 | 96 |
| Value | 62 | 65 |
| Quality | 64 | 82 |
| Growth | NR | 49 |
| Safety | 66 | 64 |
| Sentiment | 47 | 46 |
| Quality details | ||
| Profitability | 74 | 96 |
| Cash Truth | 53 | 68 |
Agenus vs Voyager TherapeuticsAgenus vs CytomX TherapeuticsAgenus vs Caribou BiosciencesAgenus vs Celldex TherapeuticsAdd a third stock →
Full analyses: Agenus · Exelixis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100